Clinical trial
Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With…
NCT03432520 · Spark Therapeutics, Inc., Industry · Active, not recruiting
Key facts
| NCT number | NCT03432520 |
|---|---|
| Title | Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A |
| Official title | A Multi-Center Evaluation of the Long-Term Safety and Efficacy of Spark-sponsored Gene Therapies in Males With Hemophilia A |
| Lead sponsor | Spark Therapeutics, Inc., Industry |
| Status | Active, not recruiting |
| Study type | Observational |
| Conditions | Hemophilia A |
| Intervention type | Genetic |
| Interventions | SPK-8011, SPK-8016 |
| Enrollment | 29 |
| Start date | Aug 14, 2018 |
| Primary completion | Dec 1, 2032 |
| Completion | Dec 1, 2032 |
| First posted | Feb 14, 2018 |
| Last update posted | Nov 29, 2024 |
| Countries | Australia, Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: